ReviewCurrent treatment options in gastroenterology2020
Update on the Management of
Review in Current treatment options in gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effectiveness of Classic Triple Therapy Compared with Alternative Regimens for EradicatingMedicina (Kaunas, Lithuania) · 2025Pooled it
- Pooled it
- Persistence ofJournal of clinical medicine · 2026Article
- Progress in immunotherapy forFrontiers in cellular and infection microbiology · 2026Review
- Global Profile of Drug Resistance Related toHealth science reports · 2025Review
- Prevalence of Helicobacter pylori infection in patients with upper gastrointestinal disorders using different methods in Khuzestan, Southwest Iran.Molecular biology reports · 2025Article
- Towards EffectiveInternational journal of molecular sciences · 2025Review
- AQbD-enhanced green RP-UPLC-PDA methodology for quantification and forced degradation studies for omeprazole, amoxicillin, and rifabutin.BMC chemistry · 2024Article
- Newer Therapies for RefractoryAntibiotics (Basel, Switzerland) · 2024Review
- Importance of risk assessment, endoscopic hemostasis, and recent advancements in the management of acute non-variceal upper gastrointestinal bleeding.World journal of clinical cases · 2024Article
- Physician perspectives of Helicobacter pylori diagnostic and treatment practices in Canada: results of a Canadian survey.BMC gastroenterology · 2024Article
- Pharmacokinetic Interactions Between Tegoprazan and the Combination of Clarithromycin, Amoxicillin and Bismuth in Healthy Chinese Subjects: An Open-Label, Single-Center, Multiple-Dosage, Self-Controlled, Phase I Trial.Clinical drug investigation · 2024Article
- Addressing Challenges in Standardizing Helicobacter pylori Treatment Protocols: Importance and Review.Cureus · 2024Review
- Effect ofJournal of enzyme inhibition and medicinal chemistry · 2023Article
- Clarithromycin-induced acute liver injury in a patient with positiveAnnals of medicine and surgery (2012) · 2023Article
- High-Salt Diet ExacerbatesJournal of personalized medicine · 2023Review
- Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects.Translational and clinical pharmacology · 2023Article
- Effect ofCurrent issues in molecular biology · 2023Review
- Update on the second-line treatment ofTherapeutic advances in gastroenterology · 2023Review
- Antimicrobial-Resistance Profile ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewOur purpose was to provide an update on methods and indications for testing and treatment selection focusing on novel modalities. RECENT
findingsIncreasing antibiotic resistance has reduced treatment effectiveness. Antibiotic resistance testing is not widely available in North America where there are insufficient resistance and susceptibility data. Quadruple regimens (bismuth-based or concomitant/non-bismuth-based) have been recommended first-line. A rifabutin-based combination product recently approved by the US Food and Drug Administration is highly effective and should simplify treatment. The potassium-competitive acid blocker vonoprazan is being evaluated as part of dual or triple combination regimens. Molecular-based genotypic testing for antibiotic resistance and an effective SUMMARY: Inability to test for antibiotic resistance renders treatment selection empiric. However, resistance to rifabutin and amoxicillin remains rare. Effective management continues to comprise appropriate diagnostic testing for active infection, utilization of an effective regimen, and post-treatment testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.